Variation in the Distribution of Trace Elements in Renal Cell Carcinoma

Autor(es)

Calvo, Fernanda Bernardes ^[1] ; Santos Junior, Dario ^[2] ; Rodrigues, Consuelo Junqueira ^[3] ; Krug, Francisco Jose ^[4] ; Marumo, Julio Takehiro ^[1] ; Schor, Nestor ^[2] ; Bellini, Maria Helena ^{[2, 1]}

Afiliação do(s) autor(es)

^[1] IPEN CNEN SP, Sao Paulo - Brazil

^[2] Univ Fed Sao Paulo, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Fac Med, Dept Cirurgia, Sao Paulo - Brazil

^[4] Ctr Energia Nucl Agr USP, Piracicaba - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BIOLOGICAL TRACE ELEMENT RESEARCH; v. 130, n. 2, p. 107-113, AUG 2009.
• Citações Web of Science: 16

Resumo

The development of cancer is a complex, multistage process during which a normal cell undergoes genetic changes that result in phenotypic alterations and in the acquisition of the ability to invade other sites. Inductively coupled plasma optical emission spectroscopy was used to estimate the contents of Al, Ca, Cd, Cr, Cu, Fe, K, Mg, Mn, Na, P, Pb, and Zn in healthy kidney and renal cell carcinoma (RCC), and significant differences were found for all elements. Along with the progression of the malignant disease, a progressive decrease of Cd and K was observed. In fact, for Cd, the concentration in stage T4 was 263.9 times lower than in stage T1, and for K, the concentration in stage T4 was 1.73 times lower than in stage T1. Progressive accumulation was detected for P, Pb, and Zn in stage T4. For P, the concentration in stage T4 was 11.1 times higher than in stage T1; for Pb, the concentration in stage T4 was 232.7 times higher than in T1; and for Zn, the concentration in T4 was 8.452 times higher than in T1. This study highlights the marked differences in the concentrations of selected trace metals in different malignant tumor stages. These findings indicate that some trace metals may play important roles in the pathogenesis of RCC. (AU)

• Processo FAPESP: 07/54253-6 - Construção e caracterização de vetor retroviral bicistrônico pL(end-IL2)SN e avaliação de sua eficácia na terapia gênica anti-tumoral
• Beneficiário: Maria Helena Bellini Marumo
• Modalidade de apoio: Auxílio à Pesquisa - Regular